INCY - Incyte Corporation
After hours:
| Previous close | 61.39 |
| Open | 61.50 |
| Bid | 60.78 x 800 |
| Ask | 62.28 x 800 |
| Day's range | 60.95 - 61.74 |
| 52-week range | 60.71 - 86.29 |
| Volume | |
| Avg. volume | 1,692,165 |
| Market cap | 13.722B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 42.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investing.com
4 big analyst cuts: PacWest slashed, stock crashes on sale talks | Pro Recap
The news comes after Bloomberg reported that the bank has been weighing a range of strategic options amid concerns about its financial health.
- Zacks
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
- Zacks
Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Zacks
Incyte (INCY) Q1 Earnings and Revenues Miss Estimates
Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
- Zacks
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
- Zacks
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
- Zacks
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
- Zacks
Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
- Zacks
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
- Zacks
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
- Zacks
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
- Zacks
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
- Zacks
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
- Zacks
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.
- Zacks
Incyte (INCY) Down 8.3% Since Last Earnings Report: Can It Rebound?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.
- Zacks
Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.
- Zacks
Top Research Reports for Mastercard, Raytheon Technologies & BP
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Raytheon Technologies Corporation (RTX) and BP p.l.c. (BP).
- Zacks
Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?
Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.
- Zacks
Incyte (INCY) Reports Positive Long-Term Data From HS Study
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
- Zacks
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
